C5aR1 Inhibition for Taxane Hypersensitivity Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Hypersensitivity reactions (HSRs) to taxanes, such as paclitaxel, docetaxel, and cabazitaxel, are unpredictable and can be life-threatening, despite current management strategies like premedication with corticosteroids and antihistamines, due to unclear mechanisms and high incidence rates.
Innovation Solution
The use of C5aR1 inhibitors to prevent or treat HSRs by blocking the C5a receptor signaling pathway activated by taxanes, which are administered before or during taxane treatment, potentially combined with corticosteroids and antihistamines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If premedication with corticosteroids and antihistamines is used, then the prevention of HSRs is attempted, but the incidence of HSRs remains high (10% with paclitaxel, 5% with docetaxel, 4% with Nab-paclitaxel)
Solution Approach 1:
The patent introduces C5aR1 inhibitors as a new intermediary substance to block the complement pathway activation triggered by taxanes. This mediator specifically targets the C5a-C5aR1 axis, preventing the downstream inflammatory cascade that leads to HSRs, thereby providing more effective prevention compared to traditional corticosteroids and antihistamines
Solution Approach 2:
The patent changes the therapeutic parameter from general anti-inflammatory and antihistaminic agents to specific complement pathway inhibitors. By targeting the specific molecular pathway (C5aR1) involved in taxane-induced HSRs, the treatment achieves higher efficacy with reduced incidence rates
2Reliability
If taxanes are administered to treat cancer, then antineoplastic activity is achieved, but HSRs occur during infusion that can be life-threatening
Solution Approach 1:
The patent applies preliminary anti-action by administering C5aR1 inhibitors before taxane infusion to prevent HSRs. This pre-treatment blocks the complement pathway activation that would otherwise be triggered by the taxane, preventing the harmful effects before they can occur while allowing the cancer treatment to proceed
3Quantity of substance
If emulsifying agents like Cremophor are added to solubilize taxanes, then water solubility is improved, but HSRs are induced through complement activation
Solution Approach 1:
The patent converts the harmful effect of complement activation into a targetable pathway. By identifying that Cremophor-induced complement activation occurs through the C5aR1 pathway, the invention specifically blocks this pathway with C5aR1 inhibitors, thereby eliminating the harmful effect while preserving the beneficial solubilization function of Cremophor
Solution Approach 2:
The patent introduces C5aR1 inhibitors as an intermediary that specifically blocks the harmful complement activation pathway triggered by Cremophor, while allowing the emulsifying agent to continue performing its useful function of solubilizing the hydrophobic taxane molecules
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Reduces the incidence and severity of HSRs by inhibiting the C5aR1 pathway, providing effective prevention and treatment options for patients at risk or experiencing HSRs.
Implementation Method 1
The use of C5aR1 inhibitors to prevent or treat HSRs by blocking the C5a receptor signaling pathway activated by taxanes
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to the use of a C5aR1 inhibitor for the prevention or treatment of a hypersensitivity reaction (HSR) to a taxane in an individual.